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Clinical Science: First Prize
What Is the Cost of Maintaining a Kidney
in Upper-Tract Transitional-Cell Carcinoma?
An Objective Analysis of Cost and Survival
Raymond W. Pak, M.D., Eric J. Moskowitz, and Demetrius H. Bagley, M.D.
Abstract
Background and Purpose: For many years, the gold standard in upper urinary tract transitional-cell carcinoma
(UT-TCC)management has been nephroureterectomywith excision of the bladder cuff. Advances in endourologic
instrumentation have allowed urologists to manage this malignancy. The feasibility and success of conservative
measures for UT-TCC have been widely published, but there has not been an objective cost analysis performed to
date. Our goal was to examine the direct costs of renal-sparing conservative measures v nephroureterectomy and
subsequent chronic kidney disease (CKD) or end-stage renal disease (ESRD). Secondary analysis includes a
discussion of survival and quality-of-life issues for both treatment cohorts.
Patients and Methods: Retrospective review of a cohort of patients treated at our institution with renal-sparing
ureteroscopic management of UT-TCC who were followed for a minimum of 2 years. The costs per case were
based on equipment, anesthesia, surgeon fees, pathologic evaluation fees, and hospital stay. ESRD and CKD costs
were estimated based on published reports.
Results: From 1996 to 2006, 254 patients were evaluated and treated for UT-TCC at our institution. A cohort of 57
patients was examined who had a minimum follow-up period of 2 years. Renal preservation in our series ap-
proached 81%, with cancer-specific survival of 94.7%. Assuming a worst-case scenario of a solitary kidney with
recurrences at each follow-up for 5 years v nephroureterectomy and dialysis for the same period, an estimated
$252,272 U.S. dollars would be saved. This savings would cover the expenses of five cadaveric renal transplan-
tations.
Conclusions: Conservative endoscopic management of UT-TCC in our experience should be the gold standard
management for low-grade and superficial-stage disease. From a cost perspective, renal-sparing UT-TCC man-
agement is effective in reducing ESRD health care expenses.
Introduction
Upper urinary tract transitional-cell carcinoma (UT-TCC) is relatively rare and accounts for no more than 5%
of all urothelial tumors and less than 10% of renal tumors.1 For
many years, the gold standard in UT-TCC management has
been radical nephroureterectomy with excision of the bladder
cuff.2 Advancements in endourologic instrument technology
have allowed urologists to manage this malignancy without
radical extirpation of the affected kidney and ureter. Current
practice patterns reveal that there is no consensus on the
management of UT-TCC; however, minimally invasive con-
servative measures are preferred.3
Many nephroureterectomies are performed yearly in the
United States when, in contrast, most UT-TCC is low grade
and superficial.4 This discordance is difficult to understand
when one considers the strong arguments for renal preser-
vation in the management of small renal tumors.5
The feasibility and success of conservative measures for
UT-TCC have been widely published, but there has not been
an objective cost analysis performed to date, despite many
cost analyses for other urologic conditions.6–8 In the era of
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cost-effectivemanagement, we should understand the costs to
preserve a kidney in the setting of UT-TCC, especially in pa-
tientswith imperative indications (bilateralUT-TCC, a solitary
kidney, and preexisting renal insufficiency). End-stage renal
disease (ESRD) accounts for a large percentage of health care
spending in the elderly.9 Moreover, survival and quality of
life when receiving dialysis can be severely diminished.9–10
Our goal was to examine the direct costs of renal-sparing
conservativemeasures v radical nephroureterectomy and sub-
sequent chronic kidney disease (CKD) or ESRD. Secondary
analysis includes a discussion of survival and quality-of-life
issues for both treatment cohorts.
Patients and Methods
We conducted a retrospective review of a selected cohort
of patients who were treated at Thomas Jefferson Hospital
with conservative renal-sparing ureteroscopic management
of UT-TCC and who were followed for a minimum of 2 years.
The data were analyzed to determine recurrence rates, pro-
gression, renal preservation, and survival. Patients with
high-grade disease and=or unresectable disease were offered
laparoscopic radical nephroureterectomy with excision of the
bladder cuff. The costs per case were based on equipment,
anesthesia time, surgeon fees, pathologic evaluation fees, and
hospital stay. Additional costs of follow-up office and imag-
ing visits were collected as well.
A standardized protocol was used with regard to upper-
tract surveillance, which included retrograde pyelography
and ureteroscopy at 3-month intervals from last recurrence
and extended to 6 months for negative surveillance. Urine
cytologic evaluation and imaging was performed at each
follow-up office visit.
Global costs for arteriovenous fistula formation, continu-
ous hemodialysis, and medical management of CKD were
estimated based on published 2007 cost reports.9 UT-TCC
survival and recurrence data and quality-of-life estimates
when receiving dialysis were collected from published papers
found on Medline. Cost analysis only included events related
to UT-TCC and excluded bladder tumor encounters for all
groups. All costs were calculated based on data for U.S. dol-
lars (USD).
Results
From 1996 to 2006, 254 patients were evaluated and treated
for UT-TCC at our institution. A cohort of 57 patients was
examined who had a minimum follow-up period of 2 years.
The average number of procedures per patientwas 10.1with a
range of 5 to 41. The patient demographics and treatment
results are summarized in Table 1. A total of eight patients had
a solitary renal unit at presentation. Renal preservation in our
series approached 81%,with cancer-specific survival of 94.7%.
Cost analysis
Our algorithm for patients in whom UT-TCC was diag-
nosed is outlined in Figure 1. The direct costs incurred at
Thomas Jefferson Hospital were calculated for ureteroscopic
laser treatment, diagnostic ureteroscopy, laparoscopic ne-
phroureterectomy with bladder cuff, and dialysis vascular
access formation (Table 2). Estimates for cadaveric renal
transplantationwere based on available published data.11 The
cost to maintain a kidney was calculated per annum and
projected over a period of 5 years against other treatment
options (Table 3, Table 4, Fig. 2).
Table 1. Patient Characteristics
Number of patients 57
Mean age (years) 65.6
Mean follow-up months (range) 53 (24–146)
Mean number of procedures 10.1
Number with solitary kidney 8
Recurrence rate 89.5%
Mean recurrences per patient 5.5
Renal preservation 80.7%
Overall survival 93%
Cancer-specific survival 94.7%
FIG. 1. Treatment algorithm
for upper tract TCC.
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A best-case scenario for an initial treatment and no recur-
rences yielded an initial cost of $5,270 for ureteroscopic laser
treatment followed by a negative surveillance visit at 3
months with subsequent negative surveillance visits that oc-
curred every 6 months, which cost $7,181 annually. A worst-
case scenario had UT-TCC recurrence at each follow-up visit,
an initial ureteroscopic laser ablation treatment that cost
$5,270, followed by re-treatment visits every 3months costing
a total of $20,634 in the first 12 months and $26,864 each
subsequent year. This scenario comprises the most aggressive
treatment algorithm reserved for patients with imperative
indications for renal preservation.
Most patients will fall between these two extremes of esti-
mated 5-year costs for renal preservation in the setting of
UT-TCC management. The estimated cost of a recurrence
per year is $18,980 USD and adds an additional outpatient
hospital visit per year. Therefore, at our institution, with an
average recurrence rate of 5.5 recurrences per patient over
a mean follow-up period of 53 months, our average cost to
maintain a kidney is $117,890 USD.
Under the most-costly scenario, an initial nephroureter-
ectomy cost of $21,764 is followed by a one-time cost of
$14,592 for arteriovenous fistula placement and then $69,758
annually for maintenance hemodialysis. Over an estimated
5-year projection, this cost rises to $385,146.
Survival analysis
The overall survival for our cohort of 57 patients was 93%
with a cancer-specific survival of 94.7%. Renal preservation
was 80.7% in our series. The cancer-specific survival for pa-
tients treated with a solitary kidney was 75% (2=8). Four pa-
tients were alive at the time of analysis with metastatic TCC
and were undergoing medical therapy.
A review of selected UT-TCC series using conservative
management was examined for survival data and is sum-
marized in Table 5.12–17 Cancer-specific survival rates ranged
from 49.3% to 100% in the selected series. Renal preservation
rates ranged from 70% to 80%.
In contrast, survival data for ESRD and hemodialysis are
not very impressive. Table 6 summarizes the age-based sur-
vival rates for patients on chronic hemodialysis over 1, 3, 5,
and 10 years.9
Discussion
The challenge of conservative management of UT-TCC is
that it requires advanced endoscopic skills, expensive equip-
ment, and compliant patients willing to undergo multiple
procedures. In this analysis, the measure of cost was used to
objectively compare the conservative management of UT-
TCC against nonrenal-sparing measures.
Table 2. Costs of Each Treatment Modality
Cost
Cost variables
Ureteroscopic
laser ablation
Diagnostic
ureteroscopy
Laparoscopic
nephroureterectomy
AV fistula
placement
Operating room costs, supplies 1,589 856 3,678
Anesthesia professional fees 825 525 1,725
Surgeon professional fees 2,200 1,580 7,100
Pathology fees 656 N=A 882
Room, nursing costs N=A N=A 8,379
Total perioperative costs 5,270 2,961 21,764 14,592
AV¼ arteriovenous; N=A¼not available.
Table 3. Annual Cost of Surveillance=Re-treatment Post-Ureteroscopic (URS) Laser Ablation
Cost ($)
Cost variables
Surveillance and re-treatment at
each follow-up visit
Surveillance only at each
follow-up visit
Ureteroscopic laser ablation 5,270 0
Diagnostic Ureteroscopy 0 2,961
Imaging
CT urography See original fax rest of column 0
Intravenous urography 661 See original fax rest of column
TCC marker studies:
Cytology 299 299
Total surveillance=re-treatment costs per visit 6,230 3,260
Number of annual follow-up visits 4 2
Sub-total annual surveillance=re-treatment costs 24,920 6,520
Once-yearly imaging:
CT urography 1,944 N=A
Intravenous urography N=A 661
Net total annual surveillance=re-treatment costs 26,864 7,181
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Recent data suggest increased risks for renal insufficiency
in patients who underwent radical nephrectomy for renal
cortical tumors, supporting the importance of renal preser-
vation.18 The argument for conservative measures in the set-
ting of a solitary kidney, bilateral UT-TCC, and preexisting
CKD are not difficult to make when considering the alterna-
tive options. This study, however, highlights the importance
of renal preservation in patients whowere considered elective
candidates for conservative (normal contralateral kidney)
management. Moreover, there are data to suggest that higher
grade tumors develop in patients with ESRD or CKD and UT-
TCC and that these patients subsequently fare worse.19 This
fact may be further reflected in our series as well as that of the
Mayo clinic.14
In patients with imperative indications for renal preserva-
tion, the cost savings over a 5-year period range from 3-fold to
almost 10-fold when compared with the ESRD and hemodi-
alysis cohort. In addition, the overall survival of conserva-
tively treated patients is much higher compared with age-
based survival statistics in patients receiving hemodialysis.
Survival rates on chronic hemodialysis for a 70-year-old pa-
tient with ESRD are 70.6%, 38.8%, and 19.2%, respectively,
at 1, 3, and 5 years. In contrast, the worst reported cancer-
specific and overall survival for conservative UT-TCC man-
agement was 49.3% and 35%, respectively, for a cohort with
an average age of 74 years with 35 months of follow-up.14
Assuming a worst-case scenario of a solitary kidney with
recurrences at each follow-up for 5 years v nephroureter-
ectomy and dialysis for the same period, an estimated
$252,272 USD would be saved, not to mention improved
quality of life and overall survival. These savings would cover
the expenses of five cadaveric renal transplantations.
Table 4. Five-Year Projected Costs After Radical Versus Renal Preserving Management
Total Cost ($)
Months since initial treatment
URS laser
ablation with
surveillance
and retreatment
URS laser
ablation with
surveillance
only LNUþCKD
LNUþAV
fistula
placement
þ hemodialysis
LNUþ kidney
transplantation
0 6,230 6,230 21,764 36,356 69,226
12 26,864 13,411 42,548 106,114 86,499
24 53,728 20,592 63,332 175,872 103,772
36 80,592 27,773 84,116 245,630 121,045
48 107,456 34,954 104,900 315,388 138,318
60 134,320 41,474 125,684 385,146 155,591
Annual cost of CKD¼
($1,294þ $438)12¼ $20,784
(US Renal Data 2007 Report)
20,784
Annual cost of HD¼ $69,758 (US Renal
Data 2007 Report)
69,758
Cost of kidney transplant¼ $47,462 (Saidi)11 47,462
Annual cost of maintaining kidney
transplant¼ $17,273 (US Renal Data
2007 Report)
17,273
URS¼ureteroscopic; LNU¼ laparoscopic nephroureterectomy; CKD¼ chronic kidney disease; AV¼ arteriovenous; HD¼hemodialysis.
FIG. 2. Projected cost over 5 years.
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Real-world costs are difficult to calculate, especially when
you include loss of productivity, morbidity, etc; therefore, this
cost analysis is very conservative and underestimates the real
cost of preserving a kidney in the setting of UT-TCC.
The issue of quality of life in UT-TCC has never been ex-
amined. Performing a MEDLINE search using quality of life
and TCC revealed only eight reports regarding bladder TCC
and urinary diversions. Using the Medical Outcomes Study
Short-Form 36-item survey (SF-36), investigators found that
patients with superficial bladder TCC who were undergoing
repeated transurethral resections had general health percep-
tions lower than normal cohorts; however, in patients who
were undergoing multiple procedures, the quality-of-life
scores for all other domains improved with four or more
transurethral resection procedures.20
This is our best estimate of UT-TCC quality of life. In con-
trast, a similarMEDLINE search using the terms quality of life
and dialysis yielded 1087 published reports. Quality-of-life
evaluations in ESRD hemodialysis patients have revealed that
patients would give up one-quarter to one-half of their re-
maining life expectancy in current health if the sacrifice would
allow them to have perfect health for a shorter time.21
Conclusions
Conservative endoscopic management of UT-TCC in our
experience should be the gold standard for low-grade and
superficial-stage disease. Not only is cancer-specific and
overall survival excellent, but also recurrences and progres-
sion are manageable and oncologically acceptable. From a
cost perspective, renal-sparing UT-TCC management is ef-
fective in reducing ESRD health care expenses.
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